Abstract
Impaired natural killer (NK) cell activity in women with endometriosis is thought to promote implantation and the progressive growth of endometrial tissue in accordance with Sampson’s hypothesis. However, the mechanisms responsible for decreased NK cell activity and the antigens recognized by NK cells in these women are not clear.
Decreased NK cell activity in the peripheral blood (PB) and peritoneal fluid (PF) of women with endometriosis was first reported by Oosterlynck et al. and subsequent investigators have identified the depression of NK cell function in women with this disorder. Decreased NK cell activity in women with endometriosis is thought to allow the implantation of endometrial tissue in the manner of a graft, but the mechanisms underlying the decline of NK cell activity remain uncertain.
We focused on the expression of HLA-G, a ligand of NK cell receptors, and its changes in eutopic endometrium during the menstrual cycle. HLA-G expression was only identified in eutopic endometrium during the menstrual phase, but not during the proliferative or secretory phases. HLA-G-expressing cells were also detected in peritoneal fluid during the menstrual phase.
Retrograde menstruation may allow HLA-G-expressing endometrial tissue to enter the peritoneal cavity, where it should be scavenged by the immune surveillance system. Because peritoneal NK cells play an important role in this system, impairment of their cytotoxicity via HLA-G could allow the survival and implantation of peritoneal endometrial cells.
In this article, we discuss the pathogenesis of endometriosis from the perspective of intraperitoneal interactions between NK cell receptors and their ligands (antigens) that enter the peritoneal cavity on cells shed from eutopic endometrium via retrograde menstruation.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Klein E, Masucci MG, Masucci G, Vanky F. Natural killer activity of human blood lymphocytes. Mol Immunol. 1982;19:1323–9.
Holmberg LA, Ault KA. Characterization of natural killer cells induced in the peritoneal exudates of mice infected with Listeria monocytogenes: a study of their tumor target specificity and their expression of murine differentiation antigens and human NK-associated antigens. Cell Immunol. 1984;89:151–68.
Klein E, Vánky F, Vose BM. Natural killer and tumor recognizing lymphocyte activity in tumor patients. Haematologia. 1978;12:107–12.
Lefkowitz M, Kornbluth J, Tomaszewski JE, Jorkasky DK. Natural killer-cell activity in cyclosporine-treated renal allograft recipients. J Clin Immunol. 1988;8:121–7.
Kwak JY, Beaman KD, Gilman-Sachs A, Ruiz JE, Schewitz D, Beer AE. Up-regulated expression of CD56+, CD56+/CD16+, and CD19+ cells in peripheral blood lymphocytes in pregnant women with recurrent pregnancy losses. Am J Reprod Immunol. 1995;34:93–9.
Werfel T, Uciechowski P, Tetteroo PA, Kurrle R, Deicher H, Schmidt RE. Activation of cloned human natural killer cells via Fc gamma RIII. J Immunol. 1989;142:1102–6.
Nitta T, Yagita H, Sato K, Okumura K. Involvement of CD56 (NKH-1/Leu-19 antigen) as an adhesion molecule in natural killer-target cell interaction. J Exp Med. 1989;170:1757–61.
Handa K, Suzuki R, Matsui H, Shimizu Y, Kumagai K. Natural killer (NK) cells as a responder to interleukin 2 (IL-2). II. IL-2-induced interferon gamma production. J Immunol. 1983;130:988–92.
Hunter CA, Timans J, Pisacane P, Menon S, Cai G, Walker W, Aste-Amezaga M, Chizzonite R, Bazan JF, Kastelein RA. Comparison of the effects of interleukin-1 alpha, interleukin-1 beta and interferon-gamma-inducing factor on the production of interferon-gamma by natural killer. Eur J Immunol. 1997;27:2787–92.
Peters PM, Ortaldo JR, Shalaby MR, Svedersky LP, Nedwin GE, Bringman TS, Hass PE, Aggarwal BB, Herberman RB, Goeddel DV, et al. Natural killer-sensitive targets stimulate production of TNF-alpha but not TNF-beta (lymphotoxin) by highly purified human peripheral blood large granular lymphocytes. J Immunol. 1986;137:2592–8.
Lozzio BB, Lozzio CB. Properties and usefulness of the original K-562 human myelogenous leukemia cell line. Leuk Res. 1979;3:363–70.
Kay HD, Fagnani R, Bonnard GD. Cytotoxicity against the K562 erythroleukemia cell line by human natural killer (NK) cells which do not bear free Fc receptors for IgG. Int J Cancer. 1979;24:141–50.
Kärre K. MHC gene control of the natural killer system at the level of the target and the host. Semin Cancer Biol. 1991;2:295–309.
Kärre K. Natural killer cell recognition of missing self. Nat Immunol. 2008;9:477–80.
Moretta A, Sivori S, Vitale M, Pende D. Existence of both inhibitory (p58) and activatory (p50) receptors for HLA-C molecules in human natural killer cells. J Exp Med. 1995;182:875–84.
Moretta A, Bottino C, Vitale M, Pende D, Biassoni R, Mingari MC, Moretta L. Receptors for HLA class-I molecules in human natural killer cells. Annu Rev Immunol. 1996;14:619–48.
Hiraki A, Kiura K, Yamane H, Nogami N, Tabata M, Takigawa N, Ueoka H, Tanimoto M, Harada M. Interleukin-12 augments cytolytic activity of peripheral blood mononuclear cells against autologous lung cancer cells in combination with IL-2. Lung Cancer. 2002;35:329–33.
Carson WE, Giri JG, Lindemann MJ, Linett ML, Ahdieh M, Paxton R, Anderson D, Eisenmann J, Grabstein K, Caligiuri MA. Interleukin (IL) 15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor. J Exp Med. 1994;180:1395–403.
Son YI, Dallal RM, Mailliard RB, Egawa S, Jonak ZL, Lotze MT. Interleukin-18 (IL-18) synergizes with IL-2 to enhance cytotoxicity, interferon-gamma production, and expansion of natural killer cells. Cancer Res. 2001;61:884–8.
Skak K, Frederiksen KS, Lundsgaard D. Interleukin-21 activates human natural killer cells and modulates their surface receptor expression. Immunology. 2008;123:575–83.
Miller JS, Prosper F, McCullar V. Natural killer (NK) cells are functionally abnormal and NK cell progenitors are diminished in granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cell collections. Blood. 1997;90:3098–105.
Uciechowski P, Werfel T, Leo R, Gessner JE, Schubert J, Schmidt RE. Analysis of CD16 + dim and CD16 + bright lymphocytes–comparison of peripheral and clonal non-MHC-restricted T cells and NK cells. Immunobiology. 1992;185:28–40.
Uciechowski P, Gessner JE, Schindler R, Schmidt RE. Fc gamma RIII activation is different in CD16+ cytotoxic T lymphocytes and natural killer cells. Eur J Immunol. 1992;22:1635–8.
Borrego F, Ulbrecht M, Weiss EH, Coligan JE, Brooks AG. Recognition of human histocompatibility leukocyte antigen (HLA)-E complexed with HLA class I signal sequence-derived peptides by CD94/NKG2 confers protection from natural killer cell-mediated lysis. J Exp Med. 1998;187:813–8.
Posch PE, Borrego F, Brooks AG, Coligan JE. HLA-E is the ligand for the natural killer cell CD94/NKG2 receptors. J Biomed Sci. 1998;5:321–31.
Braud VM, McMichael AJ. Regulation of NK cell functions through interaction of the CD94/NKG2 receptors with the nonclassical class I molecule HLA-E. Curr Top Microbiol Immunol. 1999;244:85–95.
Oosterlynck DJ, Cornillie FJ, Waer M, Vandeputte M, Koninckx PR. Women with endometriosis show a defect in natural killer activity resulting in a decreased cytotoxicity to autologous endometrium. Fertil Steril. 1991;56:45–51.
Oosterlynck DJ, Meuleman C, Waer M, Vandeputte M, Koninckx PR. The natural killer activity of peritoneal fluid lymphocytes is decreased in women with endometriosis. Fertil Steril. 1992;58:290–5.
Sampson JA. Peritoneal endometriosis due to menstrual dissemination of endometrial tissue into peritoneal cavity. Am J Obstet Gynecol. 1927;14:422–5.
Semer D, Reisler K, MacDonald PC, Casey ML. Responsiveness of human endometrial stromal cells to cytokines. Ann N Y Acad Sci. 1991;622:99–102.
Gilmore SM, Aksel S, Hoff C, Peterson RD. In vitro lymphocyte activity in women with endometriosis-an altered immune response? Fertil Steril. 1992;58:1148–52.
Garzetti GG, Ciavattini A, Provinciali M, Fabris N, Cignitti M, Romanini C. Natural killer cell activity in endometriosis: correlation between serum estradiol levels and cytotoxicity. Obstet Gynecol. 1993;81:665–8.
Wilson TJ, Hertzog PJ, Angus D, Munnery L, Wood EC, Kola I. Decreased natural killer cell activity in endometriosis patients: relationship to disease pathogenesis. Fertil Steril. 1994;62:1086–8.
Oosterlynck DJ, Meuleman C, Waer M, Koninckx PR. CO2-laser excision of endometriosis does not improve the decreased natural killer activity. Acta Obstet Gynecol Scand. 1994;73:333–7.
van der Linden PJ, de Goeij AF, Dunselman GA, van der Linden EP, Ramaekers FC, Evers JL. Expression of integrins and E-cadherin in cells from menstrual effluent, endometrium, peritoneal fluid, peritoneum, and endometriosis. Fertil Steril. 1994;61:85–90.
Dmowski WP, Gebel H, Braun DP. Decreased apoptosis and sensitivity to macrophage mediated cytolysis of endometrial cells in endometriosis. Hum Reprod Update. 1998;4:696–701.
Gebel HM, Braun DP, Tambur A, Frame D, Rana N, Dmowski WP. Spontaneous apoptosis of endometrial tissue is impaired in women with endometriosis. Fertil Steril. 1998;69:1042–7.
Meresman GF, Vighi S, Buquet RA, Contreras-Ortiz O, Tesone M, Rumi LS. Apoptosis and expression of Bcl-2 and Bax in eutopic endometrium from women with endometriosis. Fertil Steril. 2000;74:760–6.
Maeda N, Izumiya C, Yamamoto Y, Oguri H, Kusume T, Fukaya T. Increased killer inhibitory receptor KIR2DL1 expression among natural killer cells in women with pelvic endometriosis. Fertil Steril. 2002;77:297–302.
Maeda N, Izumiya C, Kusum T, Masumoto T, Yamashita C, Yamamoto Y, Oguri H, Fukaya T. Killer inhibitory receptor CD158a overexpression among natural killer cells in women with endometriosis is undiminished by laparoscopic surgery and gonadotropin releasing hormone agonist treatment. Am J Reprod Immunol. 2004;51:364–72.
Matsuoka S, Maeda N, Izumiya C, Yamashita C, Nishimori Y, Fukaya T. Expression of inhibitory-motif killer immunoglobulin-like receptor, KIR2DL1, is increased in natural killer cells from women with pelvic endometriosis. Am J Reprod Immunol. 2005;53:249–54.
Lanier LL, Corliss BC, Wu J, Leong C, Phillips JH. Immunoreceptor DAP12 bearing a tyrosine-based activation motif is involved in activating NK cells. Nature. 1998;391:703–7.
Bruhns P, Marchetti P, Fridman WH, Vivier E, Daëron M. Differential roles of N- and C-terminal immunoreceptor tyrosine-based inhibition motifs during inhibition of cell activation by killer cell inhibitory receptors. J Immunol. 1999;162:3168–75.
Yusa S, Catina TL, Campbell KS. SHP-1- and phosphotyrosine-independent inhibitory signaling by a killer cell Ig-like receptor cytoplasmic domain in human NK cells. J Immunol. 2002;168:5047–57.
LĂłpez-Botet M, BellĂłn T, Llano M, Navarro F, GarcĂa P, de Miguel M. Paired inhibitory and triggering NK cell receptors for HLA class I molecules. Hum Immunol. 2000;61:7–17.
Borrego F, Kabat J, Kim DK, Lieto L, Maasho K, Peña J, Solana R, Coligan JE. Structure and function of major histocompatibility complex (MHC) class I specific receptors expressed on human natural killer (NK) cells. Mol Immunol. 2002;38:637–60.
Kawashima M, Maeda N, Adachi Y, Takeuchi T, Yamamoto Y, Izumiya C, Hayashi K, Furihata M, Udaka K, Fukaya T. Human leukocyte antigen-G, a ligand for the natural killer receptor KIR2DL4, is expressed by eutopic endometrium only in the menstrual phase. Fertil Steril. 2009;91:343–9.
Galandrini R, Porpora MG, Stoppacciaro A, Micucci F, Capuano C, Tassi I, Di Felice A. Increased frequency of human leukocyte antigen-E inhibitory receptor. Fertil Steril. 2008;89:1490–6.
Shiroishi M, Tsumoto K, Amano K, Shirakihara Y, Colonna M, Braud VM, Allan DS, Makadzange A, Rowland-Jones S, Willcox B, Jones EY, van der Merwe PA, Kumagai I, Maenaka K. Human inhibitory receptors Ig-like transcript 2 (ILT2) and ILT4 compete with CD8 for MHC class I binding and bind preferentially to HLA-G. Proc Natl Acad Sci U S A. 2003;100:8856–61.
O’Callaghan CA, Bell JI. Structure and function of the human MHC class Ib molecules HLA-E, HLA-F and HLA-G. Immunol Rev. 1998;163:129–38.
Clements CS, Kjer-Nielsen L, McCluskey J, Rossjohn J. Structural studies on HLA-G: implications for ligand and receptor binding. Hum Immunol. 2007;68:220–6.
Vernet-Tomás Mdel M, Pérez-Ares CT, Verdú N, Molinero JL, Fernández-Figueras MT, Carreras R. The endometria of patients with endometriosis show higher expression of class I human leukocyte antigen than the endometria of healthy women. Fertil Steril. 2006;85:78–83.
Rodgers JR, Cook RG. MHC class Ib molecules bridge innate and acquired immunity. Nat Rev Immunol. 2005;5:459–71.
Valés-Gómez M, Reyburn HT, Erskine RA, López-Botet M, Strominger JL. Kinetics and peptide dependency of the binding of the inhibitory NK receptor CD94/NKG2-A and the activating receptor CD94/NKG2-C to HLA-E. EMBO J. 1999;18:4250–60.
LeMaoult J, Zafaranloo K, Le Danff C, Carosella ED. HLA-G up-regulates ILT2, ILT3, ILT4, and KIR2DL4 in antigen presenting cells, NK cells, and T cells. FASEB J. 2005;19:662–4.
Hornung D, Fujii E, Lim KH, Vigne JL, McMaster MT, Taylor RN. Histocompatibility leukocyte antigen-G is not expressed by endometriosis or endometrial tissue. Fertil Steril. 2001;75:814–7.
Barrier BF, Kendall BS, Ryan CE, Sharpe-Timms KL. HLA-G is expressed by the glandular epithelium of peritoneal endometriosis but not in eutopic endometrium. Hum Reprod. 2006;21:864–9.
Ibrahim EC, Morange M, Dausset J, Carosella ED, Paul P. Heat shock and arsenite induce expression of the nonclassical class I histocompatibility HLA-G gene in tumor cell lines. Cell Stress Chaperones. 2000;5:207–18.
Joseph LM. A healthy menstrual cycle. Clin Nutr Ins. 1997;5:1–7.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer Japan
About this chapter
Cite this chapter
Maeda, N. (2014). Role of NK Cells in Endometriosis. In: Harada, T. (eds) Endometriosis. Springer, Tokyo. https://doi.org/10.1007/978-4-431-54421-0_5
Download citation
DOI: https://doi.org/10.1007/978-4-431-54421-0_5
Published:
Publisher Name: Springer, Tokyo
Print ISBN: 978-4-431-54420-3
Online ISBN: 978-4-431-54421-0
eBook Packages: MedicineMedicine (R0)